{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "PTGX",
  "name": "Protagonist Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/PTGX/",
  "json_url": "https://orbyd.app/dossiers/PTGX.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "De-risked dual-royalty story accelerating into a binary: icotrokinra (oral IL-23, J&J) already approved and paying 6–10% royalties; rusfertide (PV, Takeda) into a Q3 2026 PDUFA. Stock at a fresh ATH ($143.29, Jul 20) as the PV theme runs — the rusfertide decision is the accelerant, but a fresh chase sits above the $125 consensus PT with a lumpy Q2 print ~Aug 3.",
  "invalidation_trigger": "A weekly close below $118 loses the July breakout shelf that launched the pre-PDUFA momentum leg. Secondary: a rusfertide Complete Response Letter, restrictive label, or delay at the Q3 2026 PDUFA, or divesiran's August 2026 Phase 2 data undercutting rusfertide's first-in-class premium.",
  "catalyst_date": "2026-08-03",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Cash $620.3M (Mar 31, 2026); first profitable quarter Q1 2026 on the $50M ICOTYDE approval milestone.",
    "Watch Silence Therapeutics (SLN) divesiran ~August 2026 PV data as a competitive read-through to rusfertide's first-in-class premium.",
    "Price sits above the $118.69 average analyst PT and at the 52-wk high ($131.87) — extended; fresh entries into the PDUFA gap carry mean-reversion risk.",
    "Q2 2026 earnings ~2026-08-03 (est.); Street sources split across Jul 30 / Aug 3 / Aug 5 — confirm exact date before the print. Milestone-lumpy P&L; read royalty run-rate and cash, not headline EPS.",
    "Rusfertide PDUFA is Q3 2026 with no exact public date; approval triggers ~$200M + $75M milestone under the Takeda opt-out structure (~$475M opt-out-linked cash in total).",
    "Cash $620.3M (Mar 31, 2026); first profitable quarter was Q1 2026 on the $50M ICOTYDE approval milestone.",
    "Silence Therapeutics (SLN) divesiran SANRECO Phase 2 topline on-track August 2026 — the live competitive read-through to rusfertide's PV premium.",
    "Price ~$136 (Jul 24) sits above the $125.15 analyst consensus but below the $145–$151 Street-high cluster; fresh entries at ATH into the PDUFA gap carry mean-reversion risk."
  ],
  "body_markdown": "## Current Thesis\nThe \"clinical-stage immunology\" label no longer describes what PTGX is. It is a dual-royalty engine: one drug approved and already paying, one about to be decided. Icotrokinra (oral IL-23 receptor peptide, J&J-partnered, branded ICOTYDE) won U.S. approval in plaque psoriasis in March 2026 and pays tiered 6–10% royalties. Rusfertide (hepcidin mimetic for polycythemia vera, Takeda-partnered) cleared Phase 3 VERIFY and carries a Q3 2026 PDUFA. The equity has re-rated from binary-biotech to royalty compounder, printing a fresh all-time high of $143.29 on Jul 20, 2026 and holding near $136 into late July. The accelerating leg an investor is buying is the rusfertide decision plus the icotrokinra IBD royalty optionality stacked behind it — with the caveat that price now trades above the $125.15 analyst consensus and a milestone-lumpy Q2 print lands in early August.\n\n## Bull Case\n- Icotrokinra approved March 2026 (ICOTYDE) for moderate-to-severe plaque psoriasis; the $50.0M approval milestone booked in Q1 2026 drove the first profitable quarter (net income $3.8M vs −$11.7M a year prior). Tiered 6–10% royalties plus up to ~$580M remaining J&J milestones.\n- Only oral peptide blocking the IL-23 receptor in a class ruled by injectable biologics (Skyrizi, Tremfya). ANTHEM-UC Phase 2b (Oct 27, 2025) showed 63.5% clinical response at week 12; J&J's Phase 3 ICONIC-UC and ICONIC-CD are enrolling, with psoriatic-arthritis Phase 3 also running — the royalty base can widen from psoriasis into ulcerative colitis and Crohn's.\n- Rusfertide VERIFY Phase 3 (n=293) hit primary: 76.9% clinical response at weeks 20–32 vs 32.9% placebo. NDA accepted with Priority Review Mar 2, 2026; Q3 2026 PDUFA; Breakthrough, Orphan and Fast Track designations; first-in-class positioning in PV.\n- The April 2026 Takeda opt-out converted a 50:50 U.S. profit split into a milestone-plus-royalty structure: $200M on exercise, a further $200M plus a $75M milestone on approval (~$475M opt-out-linked cash), with no U.S. commercial spend obligation.\n- $620.3M cash and marketable securities (Mar 31, 2026) — no financing overhang into the PDUFA. Recent target raises: Barclays Overweight $151 (Jul 14), Truist Buy $145 (Jul 7), Citizens $137, Citi $130; overall Strong Buy.\n\n## Bear Case\n- At ~$136 (Jul 24, 2026), just off the $143.29 ATH, the stock trades above the 13-analyst consensus of $125.15 — sell-side already implies mid-single-digit downside, so the frictionless part of the re-rate is behind it.\n- Rusfertide is not approved. The Q3 PDUFA is a genuine binary; VERIFY's hematocrit-control win still needs longer-term thrombotic and clinical-outcome verification that regulators weigh. A Complete Response Letter or a restrictive label resets the second-drug thesis.\n- Cash flows are partner-controlled royalty streams — Protagonist owns neither J&J's psoriasis launch cadence nor Takeda's PV commercialization; the ramp lives on payer access against entrenched biologics.\n- PV competition is live: Silence Therapeutics' divesiran (SANRECO Phase 2) targets the same iron-regulation axis, with topline on-track for August 2026 (EHA 2026 follow-up already presented) — a read-through that can compress rusfertide's first-mover premium.\n- Reported optics are lumpy; trailing figures reflect milestone timing rather than recurring product sales, so a quarter without a milestone prints ugly.\n\n## Setup & Price Structure\n- ~$136 (Jul 24), just below the $143.29 all-time high set Jul 20; 52-week range $50.49–$143.29 (~2.7x over twelve months). Market cap ~$8.75B.\n- The July leg ran from a ~$110–$113 base in early July to $143 in roughly three weeks, then consolidated a few percent below the high. Momentum structure is intact and above every rising moving average.\n- Price sits above the $125.15 consensus PT but below the Street-high cluster ($145–$151) — extended versus the average, with room versus the top targets.\n- Fresh entries at an all-time high into a binary PDUFA carry mean-reversion risk if the Q2 print or the August competitor data disappoints; the approved icotrokinra royalty is the floor that keeps this from being a zero-support pure binary.\n\n## Catalyst Calendar (next 30 days)\n\n- Rusfertide PDUFA — Q3 2026 target action date (no exact public day; some sources point to ~August). The binary accelerant: approval triggers the ~$200M + $75M milestone tranche under the Takeda structure.\n- Silence Therapeutics (SLN) divesiran SANRECO Phase 2 topline — on-track for August 2026; the tightest competitive read-through to rusfertide's PV premium.\n\n## Elapsed catalysts\n\n- Q2 2026 earnings ~2026-08-03 (est.) — Street sources cite a Jul 30–Aug 5 window. Milestone-lumpy P&L; the read is royalty run-rate and cash guidance, not headline net income. *(passed 6d ago)*\n\n## What Would Change Our Mind\n- A weekly close below $118 loses the July breakout shelf that launched the pre-PDUFA momentum leg and marks the trend as failed.\n- A rusfertide Complete Response Letter, restrictive label, or PDUFA slip at the Q3 2026 decision — the second-drug thesis is priced as an approval.\n- Divesiran SANRECO Phase 2 (August 2026) printing a clearly superior efficacy/durability profile that erodes rusfertide's first-in-class positioning.\n- The PV/precision-biotech theme flipping to SATURATED — mainstream coverage, a retail-flow flood — with no fresh company-level catalyst to extend it.\n\n## Correlation Notes\n- Tightest read-through is intra-theme: Silence Therapeutics (SLN) divesiran August 2026 data moves both the PV narrative and rusfertide's premium; SLN and PTGX trade as a mechanism pair into that print.\n- IL-23 immunology comp set: AbbVie/Skyrizi and J&J/Tremfya are the injectable incumbents icotrokinra undercuts on route of administration; AbbVie's $10.9B Apogee acquisition (Jun 2026) signals immunology M&A appetite that can re-rate oral-immunology assets.\n- Partner beta: J&J (icotrokinra royalties) and Takeda (rusfertide) — launch execution and each partner's own pipeline priorities feed the royalty stream Protagonist depends on.\n- Group beta: small/mid biotech is rate-sensitive (XBI); a macro-tightening leg pressures the whole cohort regardless of pipeline, and a binary-heavy name amplifies that beta into the PDUFA window.",
  "first_seen": "2026-07-05",
  "last_analyzed": "2026-07-25T08:37:51+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}